SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advan

Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amg

The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly

US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,

Constellation Brands (NYSE: STZ) rose in pre-market trading after reporting strong Q1 earnings and r

Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Adv

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting un

SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today ann

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinic

Top Wall Street analysts changed outlook on top names. Check our analyst ratings page for upgrades,

Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSH

Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday

One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as Feb

Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the d

Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initia

SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Genera

Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million i

One small issuer and four blank check companies went public this past week as the IPO market continu

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are

Generate Biomedicines is pursuing an IPO to fund its clinical trials and pipeline expansion efforts.